OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
228758

Arabian Company for Agricultural and Industrial Investment SCJSC

Food Retail & DistributionVerified

The company's capital structure is highly leveraged, with a debt-to-equity ratio of 2.91, indicating a significant reliance on debt financing. Liquidity is constrained, as evidenced by a current ratio of 0.81, which is below 1, suggesting the company may struggle to meet short-term obligations without additional financing. Despite a positive operating cash flow of SAR 81.85 million, the company's free cash flow is negative at SAR -108.78 million, reflecting the high capital expenditures of SAR -85.55 million. Profitability is a major concern, with a net loss of SAR -123.05 million and an operating loss of SAR -89.79 million. The return on equity is -38.46%, and the return on assets is -7.32%, both significantly below industry norms for a healthy food retail business. Gross profit of SAR 141.28 million is insufficient to cover operating expenses, contributing to the company's unprofitable position. The company's geographic and segment exposure is not explicitly detailed in the available data, but the revenue concentration in a single business sector (Food & Drug Retailing) suggests a lack of diversification. This concentration increases vulnerability to sector-specific risks, such as supply chain disruptions or regulatory changes. Growth trajectory appears negative, with the company reporting a net loss and declining profitability. The outlook for the current fiscal year is not explicitly provided, but the negative operating and net income suggest a challenging operating environment. The company's capital expenditures, while significant, have not translated into improved profitability or asset returns. Risk factors include liquidity constraints and a high debt load, which could limit the company's ability to invest in growth or respond to market changes. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a red flag. No dilution is expected in the near term, but the company's financial position may require additional equity or debt financing in the future. Recent events, such as filings and transcripts, are not detailed in the available data. However, the company's financial performance and risk profile suggest a need for strategic adjustments to improve profitability and reduce leverage.

30-day price · 2287+0.56 (+2.2%)
Low$25.00High$28.36Close$25.70As of18 May, 00:00 UTC
Profile
CompanyArabian Company for Agricultural and Industrial Investment SCJSC
Ticker2287.SE
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryFood Retail & Distribution
AI analysis

Business. Arabian Company for Agricultural and Industrial Investment SCJSC operates in the Food Retail & Distribution industry, focusing on the retail and distribution of food and drug products.

Classification. The company is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Food Retail & Distribution industry with a confidence level of 0.92.

The company's capital structure is highly leveraged, with a debt-to-equity ratio of 2.91, indicating a significant reliance on debt financing. Liquidity is constrained, as evidenced by a current ratio of 0.81, which is below 1, suggesting the company may struggle to meet short-term obligations without additional financing. Despite a positive operating cash flow of SAR 81.85 million, the company's free cash flow is negative at SAR -108.78 million, reflecting the high capital expenditures of SAR -85.55 million. Profitability is a major concern, with a net loss of SAR -123.05 million and an operating loss of SAR -89.79 million. The return on equity is -38.46%, and the return on assets is -7.32%, both significantly below industry norms for a healthy food retail business. Gross profit of SAR 141.28 million is insufficient to cover operating expenses, contributing to the company's unprofitable position. The company's geographic and segment exposure is not explicitly detailed in the available data, but the revenue concentration in a single business sector (Food & Drug Retailing) suggests a lack of diversification. This concentration increases vulnerability to sector-specific risks, such as supply chain disruptions or regulatory changes. Growth trajectory appears negative, with the company reporting a net loss and declining profitability. The outlook for the current fiscal year is not explicitly provided, but the negative operating and net income suggest a challenging operating environment. The company's capital expenditures, while significant, have not translated into improved profitability or asset returns. Risk factors include liquidity constraints and a high debt load, which could limit the company's ability to invest in growth or respond to market changes. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a red flag. No dilution is expected in the near term, but the company's financial position may require additional equity or debt financing in the future. Recent events, such as filings and transcripts, are not detailed in the available data. However, the company's financial performance and risk profile suggest a need for strategic adjustments to improve profitability and reduce leverage.
Key takeaways
  • The company is highly leveraged with a debt-to-equity ratio of 2.91, indicating a significant reliance on debt financing.
  • Profitability is severely underperforming, with a return on equity of -38.46% and a return on assets of -7.32%.
  • Liquidity is constrained, with a current ratio of 0.81 and a negative free cash flow of SAR -108.78 million.
  • The company's business is concentrated in a single sector, increasing vulnerability to sector-specific risks.
  • Growth trajectory is negative, with declining profitability and no clear path to improvement in the near term.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySAR
Revenue$1.35B
Gross profit$141.3M
Operating income-$89.8M
Net income-$123.1M
R&D
SG&A
D&A
SBC
Operating cash flow$81.9M
CapEx-$85.5M
Free cash flow-$108.8M
Total assets$1.68B
Total liabilities$1.36B
Total equity$319.9M
Cash & equivalents
Long-term debt$930.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$1.35B-$89.8M-$123.1M-$108.8M
FY-1$1.24B$50.6M$27.1M-$25.7M
FY-2$1.10B$77.8M$62.7M-$87.4M
FY-3$1.03B$64.6M$50.2M-$131.1M
FY-4$729.1M$886.8k-$14.3M-$28.3M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$1.68B$319.9M
FY-1$1.43B$460.6M
FY-2$1.19B$436.6M$23.1M
FY-3$954.9M$125.6M
FY-4$778.2M$45.2M$6.9M
PeriodOCFCapExFCFSBC
FY0$81.9M-$85.5M-$108.8M
FY-1$74.4M-$119.2M-$25.7M
FY-2$159.3M-$191.3M-$87.4M
FY-3$117.6M-$221.3M-$131.1M
FY-4$118.3M-$55.5M-$28.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$422.1M
FQ-1$356.1M-$126.6M-$141.9M-$99.8M
FQ-2$327.2M$6.4M$148.9k-$30.3M
FQ-3$331.9M$26.5M$18.6M$20.2M
FQ-4$320.1M$12.6M$21.2M$36.9M
FQ-5$316.4M$3.1M-$6.3M-$40.4M
FQ-6$308.3M$11.6M$4.4M$1.8M
FQ-7$290.8M$12.0M$7.0M$3.8M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$318.5M
FQ-1$1.68B$319.9M
FQ-2$1.72B$465.2M$13.2M
FQ-3$1.57B$485.4M$47.1M
FQ-4$1.55B$481.8M
FQ-5$1.43B$460.6M
FQ-6$1.36B$468.1M
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1$81.9M-$85.5M-$99.8M
FQ-2$97.2M-$87.7M-$30.3M
FQ-3-$14.7M-$20.3M$20.2M
FQ-4-$2.7M-$1.9M$36.9M
FQ-5$74.4M-$119.2M-$40.4M
FQ-6$94.0M-$68.4M$1.8M
FQ-7$77.9M-$49.2M$3.8M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$319.9M
Net cash-$930.6M
Current ratio0.8
Debt/Equity2.9
ROA-7.3%
ROE-38.5%
Cash conversion-67.0%
CapEx/Revenue-6.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 234 companies
Metric2287Activity
Op margin-6.6%2.8% medp25 0.9% · p75 5.9%bottom quartile
Net margin-9.1%1.8% medp25 0.3% · p75 3.6%bottom quartile
Gross margin10.5%24.1% medp25 13.8% · p75 31.4%bottom quartile
CapEx / revenue-6.3%-2.0% medp25 -3.8% · p75 -1.0%bottom quartile
Debt / equity291.0%56.0% medp25 14.0% · p75 113.8%top quartile
Observations
IR observations
Mean price target34.80 SAR
Median price target34.80 SAR
High price target34.80 SAR
Low price target34.80 SAR
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate1.38 SAR
Last actual EPS-4.10 SAR
Source: analysis-pipeline (hybrid)Generated: 2026-05-19 00:38 UTCJob: 7c9b5669